EPO and malignant colon neoplasm: The current work investigates the effect of the simultaneous use of erythropoietin (Epo) and LFM-A13 (BTK inhibitor) on the viability of DLD-1 and HT-29 colon cancer cells and on their growth in xenografts, as well as its putative mechanism of cytotoxicity.